CRDF Cardiff Oncology Inc
Price (delayed)
$3.01
Market cap
$200.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$150.29M
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to
Highlights
The equity has surged by 68% since the previous quarter and by 19% year-on-year
The gross profit has increased by 40% YoY
The quick ratio has grown by 48% from the previous quarter but it has contracted by 4.2% YoY
The net income has declined by 10% year-on-year and by 6% since the previous quarter
Cardiff Oncology's EPS has decreased by 2.2% YoY
Key stats
What are the main financial stats of CRDF
Market
Valuations
Earnings
Shares outstanding
66.52M
Market cap
$200.24M
Enterprise value
$150.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
209.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
220.05
Revenue
$683,000
Gross profit
$683,000
Operating income
-$48.65M
Net income
-$45.43M
EBIT
-$45.43M
EBITDA
-$45.03M
Free cash flow
-$37.77M
Per share
Balance sheet
Liquidity
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.79
Book value per share
$1.62
Revenue per share
$0.01
TBVPS
$2.04
Total assets
$97.19M
Total liabilities
$14.24M
Debt
$1.52M
Equity
$82.95M
Working capital
$81.63M
Debt to equity
0.02
Current ratio
7.08
Quick ratio
6.89
Net debt/EBITDA
1.11
Margins
Efficiency
Dividend
EBITDA margin
-6,592.5%
Gross margin
100%
Net margin
-6,651.7%
Operating margin
-7,123.1%
Return on assets
-60.6%
Return on equity
-74%
Return on invested capital
-122.6%
Return on capital employed
-54.2%
Return on sales
-6,651.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRDF stock price
How has the Cardiff Oncology stock price performed over time
Intraday
-1.63%
1 week
-14.97%
1 month
-29.01%
1 year
-43.95%
YTD
-30.65%
QTD
-4.14%
Financial performance
How have Cardiff Oncology's revenue and profit performed over time
Revenue
$683,000
Gross profit
$683,000
Operating income
-$48.65M
Net income
-$45.43M
Gross margin
100%
Net margin
-6,651.7%
The gross profit has increased by 40% YoY
Cardiff Oncology's revenue has increased by 40% YoY
The operating margin rose by 23% year-on-year but it has declined by 6% since the previous quarter
Cardiff Oncology's net margin has increased by 22% YoY but it has decreased by 7% QoQ
Growth
What is Cardiff Oncology's growth rate over time
Valuation
What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
1.86
P/S
209.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
220.05
Cardiff Oncology's EPS has decreased by 2.2% YoY
The equity has surged by 68% since the previous quarter and by 19% year-on-year
The stock's price to book (P/B) is 33% less than its last 4 quarters average of 2.8 and 14% less than its 5-year quarterly average of 2.2
The P/S is 48% less than the 5-year quarterly average of 410.6 and 17% less than the last 4 quarters average of 256.3
Cardiff Oncology's revenue has increased by 40% YoY
Efficiency
How efficient is Cardiff Oncology business performance
The company's return on invested capital has shrunk by 104% YoY and by 18% QoQ
Cardiff Oncology's return on equity has decreased by 47% YoY
CRDF's return on assets is down by 37% year-on-year
Cardiff Oncology's return on sales has increased by 22% YoY but it has decreased by 7% QoQ
Dividends
What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRDF.
Financial health
How did Cardiff Oncology financials performed over time
Cardiff Oncology's total assets has surged by 55% QoQ and by 19% YoY
The company's current ratio rose by 49% QoQ but it fell by 4.5% YoY
Cardiff Oncology's debt is 98% lower than its equity
The equity has surged by 68% since the previous quarter and by 19% year-on-year
The debt to equity has contracted by 33% from the previous quarter and by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.